02787nas a2200265   4500008004100000020001400041024001700055245008300072210006900155260029900224300001600523490000700539520174100546100001802287700001802305700002102323700002102344700001702365700002102382700001502403700001602418700002302434700001902457856004502476       2014                        eng d  a0041-1132  awdn, 041736000aA comparison of adverse reaction rates for PAS C versus plasma platelet units.0 acomparison of adverse reaction rates for PAS C versus plasma pla  a(C) 2014 John Wiley & Sons, Ltdb(1)Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota(2)Mayo Clinic, Rochester, Minnesota(3)Department of Pathology and Cell Biology, Columbia University Medical Center-New York Presbyterian Hosc2014  a1927 - 19340 v543 aBACKGROUND: Plasma constituents have been implicated in some types of platelet (PLT) transfusion reactions. Leukoreduced apheresis PLTs stored in InterSol have 65% less plasma than apheresis PLTs stored in 100% plasma (PPs). This study compared transfusion reaction rates in InterSol PLTs (PLT additive solution [PAS] C) versus PPs., STUDY DESIGN AND METHODS: The study design was an open-label, nonrandomized retrospective review. Statistical methods were applied to substantiate noninferiority and superiority of PAS C compared to PP in terms of transfusion reaction rates. Adverse reactions (ARs) were categorized using the Biovigilance Component of the National Healthcare Safety Network. Active surveillance was used to monitor all transfusions, both with ARs and without ARs., RESULTS: A total of 14,005 transfusions from six study sites were included, with 9845 PP transfusions given to 2202 patients and 4160 PAS C to 1444 patients. A total of 165 ARs were reported. Percentages of transfusions with ARs were 1.37% for PPs, 0.55% for PAS C, and 1.13% overall. The relative risk (RR) for PAS C versus PPs was calculated as 0.403 with an upper confidence limit (UCL) of 0.663. Overall, ARs with the highest incidence were allergic transfusion reactions (ATRs) and febrile nonhemolytic transfusion reactions (FNHTRs), at 0.66 and 0.40% of total transfusions reported, respectively. The relative risks (UCLs) for ATRs and FNHTRs, respectively, were 0.350 (0.686) and 0.336 (0.827)., CONCLUSIONS: PAS C PLTs were statistically superior and noninferior to PPs with respect to the transfusion-related AR rate. PAS C noninferiority and superiority were also demonstrated for ATRs and FNHTRs, separately., (C) 2014 John Wiley & Sons, Ltd1 aCohn, Claudia1 aStubbs, James1 aSchwartz, Joseph1 aFrancis, Richard1 aGoss, Cheryl1 aCushing, Melissa1 aShaz, Beth1 aMair, David1 aBrantigan, Barbara1 aHeaton, Andrew  uhttp://613633.bywedr.asia/reference/4212